Pinned straw:
@Rick and @Bear77 - agree with you both. I'm in at $12. $LYL is a very well-run engineering company. Of course, as @Rick notes, if FY24 ends up being strong, it could step up out of reach. It can be argued to be not all that expensive today, even at $13.70.
But then again, its most closely related commodity has had a phenomenal 10-year run. And I can't take a further 5-10 year view on that, so I will be conservative even if that means I never get to own it.
While you've both put it on my radar screen through your posts here, it separately keeps popping up favourably on my sector comparisons of engineers. In particular, it seems to score well on retention and culture.
(It's on my "priority" shortlist - the list of 10-15, as opposed to the "long" shortlist of more than 30)
I don't understand why no analysts appear to be covering it - at a market cap of >$0.5bn its not exactly micro.
I hope you can get back in real life @Bear77. I think $12 wouldn’t be a bad price to get back in. What are your thoughts?
Lycopodium has grown to #6 in our real life portfolios and makes up about 5.8% by value. Unfortunately I didn’t add in Strawman. We’ve added shares a few times this year IRL after pull backs. I think LYL is approaching its valuation, but could still have some to go, depending on the FY24 result.
Back in February management confirmed FY24 guidance of $345 million in revenue, and NPAT between $46 million and $50 million compared to $46.8 million last year. Given 1H24 NPAT was $30 million compared to $20 million in 1H23, I think management, in their usual style, are being ultra conservative with their guidance. To reach the upper end of guidance 2H24 NPAT only needs to come in at $20 million. I think they’ll breeze that in.
Looking at the metrics I expect ROE will be close to 40%, similar to last year. I expect earnings to be between $1.26 to $1.50 per share based on NPAT between $50 million and $60 million, compared to $1.18 per share last year. That puts PE somewhere between 9 and 11 times FY24 earnings. Over the past 8 years the PE ratio has ranged between 7 and 15 with the median around 10. A simple PE valuation using 10x FY24 earnings puts the valuation somewhere between $13 and $15 per share.
If Lycopodium could maintain an ROE of 39%, you could expect a return of 15% per year going forward on the current share price of $13.70 (McNiven’s formula). About 10% of that would be in dividends (includes franking credits and assumes a payout ratio of 60%) and about 5% would be growth.
Good luck Bear!